The long-term strategy for AI in drug discovery is a two-step process. First, create an AI platform to design effective drugs. Second, after a dozen or so AI-designed drugs succeed, use that data to convince regulators to trust AI predictions, potentially allowing future drugs to skip steps like animal testing and accelerate trials.

Beyond early discovery, LLMs deliver significant value in clinical trials. They accelerate timelines by automating months of post-trial documentation work. More strategically, they can improve trial success rates by analyzing genomic data to identify patient populations with a higher likelihood of responding to a treatment.

Digital twins and virtual trials are not currently used to replace human clinical trials. Instead, they serve as powerful simulation tools to 'test drive' protocols with virtual patient data. This helps create synthetic control arms, anticipate challenges, and optimize trial designs before launching a costly real-world study.

The $5 billion cost to develop a drug is primarily driven by the high failure rate (9 out of 10) in late-stage trials. AI's biggest financial impact will be predicting which drugs will succeed, drastically reducing wasted R&D. This efficiency is what will ultimately make drugs more affordable.

The transformational power of AI in life sciences isn't just designing novel molecules, which fails to solve the costly clinical development bottleneck. Instead, agentic AI provides immense leverage to individual scientists, automating tasks like protocol writing and experiment analysis that previously took weeks.

While most focus on AI for drug discovery, Recursion is building an AI stack for clinical development, where 70% of costs lie. By using real-world data to pinpoint patient locations and causal AI to predict responders, they are improving trial enrollment rates by 1.5x. This demonstrates a holistic, end-to-end AI strategy that addresses bottlenecks across the entire value chain, not just the initial stages.

It's impossible to generate human data at the scale of in silico experiments. The key is to create highly accurate simulations of human physiology (digital twins) and then validate their predictions with limited, strategic human data. If the model proves reliable, it could drastically accelerate R&D.

While AI for novel drug discovery has lofty goals, its most practical value lies in accelerating development. This includes applying AI to de-risked assets for new indications, improving delivery methods, and designing faster, more effective clinical trials, which is where the real bottleneck lies.

While AI is on the verge of cracking preclinical challenges, the biggest problem is the high drug failure rate in human trials. The next wave of innovation will use AI to design molecules for properties that predict human efficacy, addressing the fundamental reason drugs fail late-stage.